BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36408463)

  • 1. Overexpression of Pleckstrin Homology Domain-Containing Family A Member 4 Is Correlated with Poor Prognostic Outcomes and Immune Infiltration in Lower-Grade Glioma.
    Huang B; Pan W; Wang W; Wang Y; Liu P; Geng W
    Dis Markers; 2022; 2022():1292648. PubMed ID: 36408463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma.
    Zhi W; Wang Y; Jiang C; Gong Y; Chen Q; Mao X; Deng W; Zhao S
    Front Immunol; 2023; 14():1128244. PubMed ID: 37818357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PLEKHA4 Is a Prognostic Biomarker and Correlated with Immune Infiltrates in Glioma.
    Zhang W; Li L; Bian PP; Luo QP; Xiong ZT
    Biomed Res Int; 2023; 2023():4504474. PubMed ID: 36714030
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Gao X; Liu Y; Hong S; Yang H; Guan B; Ma X
    J Integr Neurosci; 2023 Aug; 22(5):135. PubMed ID: 37735118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SLC10A3 Is a Prognostic Biomarker and Involved in Immune Infiltration and Programmed Cell Death in Lower Grade Glioma.
    Ma W; Mei P
    World Neurosurg; 2023 Oct; 178():e595-e640. PubMed ID: 37543196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of COL1A1 associated with immune infiltration in brain lower grade glioma.
    Ren J; Da J; Hu N
    PLoS One; 2022; 17(7):e0269533. PubMed ID: 35789341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and validation of an individualized prognostic signature of lower-grade glioma based on nine immune related long non-coding RNA.
    Maimaiti A; Jiang L; Wang X; Shi X; Pei Y; Hao Y; Paerhati H; Zibibula Y; Abudujielili A; Kasimu M
    Clin Neurol Neurosurg; 2021 Feb; 201():106464. PubMed ID: 33454543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
    Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
    Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
    Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
    Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abundant expression of ferroptosis-related SAT1 is related to unfavorable outcome and immune cell infiltration in low-grade glioma.
    Mou Y; Zhang L; Liu Z; Song X
    BMC Cancer; 2022 Feb; 22(1):215. PubMed ID: 35227235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PLEKHA4 promotes glioblastoma progression through apoptosis inhibition, tumor cell migration, and macrophage infiltration.
    He Y; Zheng W; Huo Y; Sa L; Zhang H; He G; Shang P
    Immunobiology; 2023 Nov; 228(6):152746. PubMed ID: 37980830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated RECQL1 expression predicts poor prognosis and associates with tumor immune infiltration in low-grade glioma.
    Wang G; Cen Y; Wang C; Xiang W; Li S; Ming Y; Chen L; Zhou J
    Transl Cancer Res; 2022 Jun; 11(6):1552-1564. PubMed ID: 35836526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study on the Prognostic Values of Dynactin Genes in Low-Grade Glioma.
    Su X; Li H; Chen S; Qin C
    Technol Cancer Res Treat; 2021; 20():15330338211010143. PubMed ID: 33896271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic biomarker SGSM1 and its correlation with immune infiltration in gliomas.
    Li J; Wang J; Ding Y; Zhao J; Wang W
    BMC Cancer; 2022 Apr; 22(1):466. PubMed ID: 35484511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serine Incorporator 2 (SERINC2) Expression Predicts an Unfavorable Prognosis of Low-Grade Glioma (LGG): Evidence from Bioinformatics Analysis.
    Qi C; Lei L; Hu J; Wang G; Liu J; Ou S
    J Mol Neurosci; 2020 Oct; 70(10):1521-1532. PubMed ID: 32642801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma.
    Cao Y; Zhu H; Chen Q; Huang H; Xie D; Li X; Jiang X; Ren C; Peng J
    Front Pharmacol; 2022; 13():914667. PubMed ID: 36091778
    [No Abstract]   [Full Text] [Related]  

  • 20. Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma.
    Qiu H; Tian W; He Y; Li J; He C; Li Y; Liu N; Li J
    Front Oncol; 2021; 11():654350. PubMed ID: 33954112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.